ALPS Medical Breakthroughs ETF (SBIO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALPS Medical Breakthroughs ETF (SBIO) trades at $68.56. The ALPS Medical Breakthroughs ETF (SBIO) aims to replicate the performance of the S-Network Medical Breakthroughs Index (PMBI). Market cap: $218M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SBIO: SBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SBIO against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SBIO.
How is this calculated? →ALPS Medical Breakthroughs ETF (SBIO) Financial Services Profile
ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund seeking to mirror the S-Network Medical Breakthroughs Index, targeting companies poised for innovation in the medical sector. With a focus on breakthrough potential, SBIO offers investors exposure to a dynamic segment within the broader healthcare landscape, albeit with inherent market risks.
What Is the Investment Thesis for SBIO?
SBIO presents an investment opportunity for those seeking exposure to the medical breakthroughs sector. With a market capitalization of $218M and a beta of 1.34, SBIO offers a potentially high-growth but also volatile investment. The fund's value is tied to the performance of the S-Network Medical Breakthroughs Index (PMBI), which focuses on companies with innovative medical technologies. A key growth catalyst is the ongoing advancements in medical science and technology, which could drive the performance of companies held within the ETF. However, potential risks include regulatory hurdles, clinical trial failures, and market volatility affecting the healthcare sector. Investors should monitor the performance of the PMBI and the financial health of the companies within the ETF to assess its long-term value.
Based on FMP financials and quantitative analysis
SBIO Key Highlights
Market Cap of $218M indicates a relatively small fund size, which can lead to higher volatility.
- Beta of 1.34 suggests that SBIO is more volatile than the overall market.
- The ETF tracks the S-Network Medical Breakthroughs Index (PMBI), providing exposure to companies with high innovation potential.
- SBIO offers targeted exposure to the medical breakthroughs sector, which can be beneficial for investors seeking diversification within the healthcare industry.
- The fund's performance is directly linked to the success of medical companies in developing and commercializing new technologies and treatments.
Who Are SBIO's Competitors?
SBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AFMC First Trust Active Factor Mid Cap ETF | $40.94 | -0.78% | $123M | 47 |
| CIL VictoryShares International Volatility Wtd ETF | $56.91 | +0.14% | $102M | 44 |
| EVX VanEck Environmental Services ETF | $41.28 | -0.58% | $103M | 46 |
| FITE State Street SPDR S&P Kensho Future Security ETF | $111.30 | -2.46% | $115M | 47 |
| IFGL iShares International Developed Real Estate ETF | $22.80 | +0.31% | $81.9M | 47 |
| LIEN Chicago Atlantic BDC, Inc. | $9.74 | +2.53% | $223M | 86 |
| CAGPF Samara Asset Group plc | $2.49 | +0.00% | $228M | 67 |
| HTFC Horizon Technology Finance Corp. | $24.97 | +0.00% | $230M | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SBIO's Key Strengths?
Targeted exposure to the high-growth medical breakthroughs sector.
- Diversified portfolio of innovative medical companies.
- Transparent and rules-based index methodology.
- Managed by an experienced ETF provider.
What Are SBIO's Weaknesses?
Relatively small market capitalization, leading to potential volatility.
- Concentration in the healthcare sector, increasing sector-specific risk.
- Dependence on the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Subject to regulatory and clinical trial risks.
What Could Drive SBIO Stock Higher?
Positive clinical trial results for portfolio companies.
- Regulatory approvals for new medical treatments and technologies.
- Advancements in medical science and technology driving innovation.
- Increased investment in healthcare research and development.
What Are the Key Risks for SBIO?
Regulatory setbacks and delays in approvals.
- Clinical trial failures and negative data releases.
- Market volatility and economic downturns affecting the healthcare sector.
- Competition from other healthcare and biotechnology companies.
- Patent protection and intellectual property disputes.
What Are the Growth Opportunities for SBIO?
- Increased Investment in Healthcare Innovation: The global healthcare sector is witnessing increased investment in research and development, particularly in areas such as gene therapy, personalized medicine, and digital health. This trend presents a significant growth opportunity for SBIO, as it provides exposure to companies at the forefront of these innovations. The global biotechnology market is projected to reach $1.5 trillion by 2028, growing at a CAGR of 12.3%. SBIO can capitalize on this growth by identifying and investing in companies that are driving these advancements.
- Aging Population and Chronic Diseases: The global aging population and the rising prevalence of chronic diseases are driving demand for new and innovative medical treatments. This trend creates a favorable environment for companies focused on medical breakthroughs. SBIO can benefit from this demographic shift by investing in companies that are developing therapies and technologies to address age-related and chronic conditions. The global market for chronic disease management is expected to reach $12.8 billion by 2027, offering a substantial growth opportunity for SBIO.
- Advancements in Medical Technology: Rapid advancements in medical technology, such as artificial intelligence, robotics, and nanotechnology, are transforming the healthcare landscape. These technologies are enabling the development of more effective and personalized treatments. SBIO can capitalize on these advancements by investing in companies that are leveraging these technologies to develop innovative medical solutions.
- Regulatory Approvals and Market Access: The successful navigation of regulatory approval processes and the ability to gain market access are critical for the growth of medical companies. SBIO can benefit from companies that are able to secure regulatory approvals for their products and expand their market reach. The ETF's investment strategy should focus on identifying companies with strong regulatory strategies and the potential to commercialize their innovations globally.
- Strategic Partnerships and Acquisitions: Strategic partnerships and acquisitions can accelerate the growth of medical companies by providing access to new technologies, markets, and resources. SBIO can benefit from companies that are actively pursuing strategic partnerships and acquisitions to expand their business. The ETF's investment strategy should consider the potential for portfolio companies to engage in value-creating transactions that enhance their growth prospects. The global healthcare mergers and acquisitions market is expected to remain active, offering opportunities for SBIO's portfolio companies to enhance their value.
What Are SBIO's Competitive Advantages?
- First-mover advantage in offering a dedicated ETF focused on medical breakthroughs.
- Brand recognition and reputation of ALPS Advisors, Inc.
- Proprietary index methodology for selecting companies with breakthrough potential.
What Does SBIO Do?
The ALPS Medical Breakthroughs ETF (SBIO) is designed to provide investment results that closely correspond, before fees and expenses, to the performance of the S-Network Medical Breakthroughs Index (PMBI). This index focuses on identifying and tracking companies within the medical sector that are demonstrating significant breakthrough potential. The ETF serves as a vehicle for investors seeking exposure to innovative companies that are developing and commercializing new medical technologies, treatments, and therapies. SBIO's underlying index uses a rules-based methodology to select companies, aiming to capture those with the highest potential for growth and innovation. The ETF's investment strategy involves holding a portfolio of stocks that mirrors the composition of the PMBI, thereby providing investors with diversified exposure to the medical breakthroughs sector. SBIO does not have a founding story in the traditional sense of a company, as it is an ETF created and managed by ALPS Advisors, Inc. to track a specific index. Its evolution is tied to the performance and composition of the S-Network Medical Breakthroughs Index. The ETF's geographic reach is global, as it can invest in companies listed on various exchanges worldwide, provided they meet the index's selection criteria.
What Products and Services Does SBIO Offer?
- Tracks the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Invests in companies with significant breakthrough potential in the medical sector.
- Provides investors with exposure to innovative medical technologies, treatments, and therapies.
- Offers a diversified portfolio of stocks within the medical breakthroughs sector.
- Seeks to replicate the returns of the PMBI before fees and expenses.
- Manages a portfolio of stocks that mirrors the composition of the PMBI.
How Does SBIO Make Money?
- Generates revenue through management fees charged to investors.
- Aims to provide investment results that correspond to the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Offers a vehicle for investors seeking exposure to innovative companies in the medical sector.
What Industry Does SBIO Operate In?
The asset management industry is characterized by intense competition and evolving investor preferences. ETFs like SBIO compete with other healthcare and biotechnology-focused funds, as well as broader market index funds. The medical breakthroughs sector is driven by innovation, regulatory approvals, and market demand for new treatments. The industry is subject to regulatory scrutiny, clinical trial risks, and patent protection challenges. SBIO's success depends on its ability to accurately track the PMBI and provide investors with exposure to high-growth medical companies.
Who Are SBIO's Key Customers?
- Retail investors seeking exposure to the medical breakthroughs sector.
- Institutional investors looking for diversified healthcare investments.
- Financial advisors seeking to provide clients with access to innovative medical companies.
ALPS Medical Breakthroughs ETF (SBIO) Valuation Context
Valued at $218M, SBIO is classified as a micro-cap stock.
Key Financial Metrics
Return on equity for ALPS Medical Breakthroughs ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. SBIO trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
SBIO Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the high-growth medical breakthroughs sector.
- Diversified portfolio of innovative medical companies.
- Transparent and rules-based index methodology.
- Managed by an experienced ETF provider.
Bear Case
- Relatively small market capitalization, leading to potential volatility.
- Concentration in the healthcare sector, increasing sector-specific risk.
- Dependence on the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Subject to regulatory and clinical trial risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SBIO Latest News
No recent news available for SBIO.
SBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SBIO.
Price Targets
Wall Street price target analysis for SBIO.
SBIO MoonshotScore
What does this score mean?
The MoonshotScore rates SBIO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
ALPS Medical Breakthroughs ETF Financial Services Stock: Key Questions Answered
What does ALPS Medical Breakthroughs ETF do?
The ALPS Medical Breakthroughs ETF (SBIO) is designed to track the performance of the S-Network Medical Breakthroughs Index (PMBI). This index focuses on identifying and investing in companies within the medical sector that are developing and commercializing innovative medical technologies, treatments, and therapies.
What are the main risks for SBIO?
The main risks for SBIO include regulatory hurdles, clinical trial failures, and market volatility affecting the healthcare sector. The success of the ETF is heavily reliant on the ability of its portfolio companies to obtain regulatory approvals for their products and successfully commercialize them. Clinical trial failures can significantly impact the value of these companies.
How does ALPS Medical Breakthroughs ETF generate revenue in the financial services sector?
As an exchange-traded fund (ETF), ALPS Medical Breakthroughs ETF (SBIO) generates revenue primarily through management fees. These fees are charged to investors as a percentage of the assets under management (AUM). The ETF's investment objective is to track the performance of the S-Network Medical Breakthroughs Index (PMBI), and ALPS, as the fund's manager, is compensated for providing this service.
What is ALPS Medical Breakthroughs ETF's approach to managing risk within its portfolio?
ALPS Medical Breakthroughs ETF (SBIO) manages risk primarily through diversification and adherence to its underlying index, the S-Network Medical Breakthroughs Index (PMBI). By investing in a basket of companies within the medical breakthroughs sector, the ETF reduces the impact of any single company's performance on the overall portfolio.
What are the key factors to evaluate for SBIO?
Evaluate SBIO on fundamentals, analyst consensus, and risk factors. SBIO presents an investment opportunity for those seeking exposure to the medical breakthroughs sector. Not financial advice.
How frequently does SBIO data refresh on this page?
SBIO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SBIO's recent stock price performance?
ALPS Medical Breakthroughs ETF (SBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the high-growth medical breakthroughs sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SBIO overvalued or undervalued right now?
ALPS Medical Breakthroughs ETF (SBIO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for SBIO, so some information may be incomplete.
- The information provided is based on publicly available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.